Jo
Posted:
March 04, 2026
Location:
Maynila, Metro Manila, Philippines
Job Description
Joincare Pharma Philippines, Inc. is a subsidiary of Joincare Pharmaceutical Group Industry Co., Ltd established in 1992 and headquartered in Shenzhen China. Joincare Group is an innovative scientific research-based integrated pharmaceutical group.
The company has always adhered to the concept of scientific and technological innovation as the cornerstone, implementing a dual-driver strategy focused on innovative drugs and high-barrier complex formulation technology platforms. To date, it has developed four major platforms for the research and development of innovative high-barrier complex formulations.
The group owns two major listed companies, Joincare and Livzon Pharmaceutical, as well as more than 20 major holding subsidiaries, with a workforce of over 14,000 employees. By the end of 2023, the company's total assets amounted to 5 billion US$, with an operational revenue of 2.3 billion US$.
Position Summary:
This role is responsible for building and expanding the commerci...
The company has always adhered to the concept of scientific and technological innovation as the cornerstone, implementing a dual-driver strategy focused on innovative drugs and high-barrier complex formulation technology platforms. To date, it has developed four major platforms for the research and development of innovative high-barrier complex formulations.
The group owns two major listed companies, Joincare and Livzon Pharmaceutical, as well as more than 20 major holding subsidiaries, with a workforce of over 14,000 employees. By the end of 2023, the company's total assets amounted to 5 billion US$, with an operational revenue of 2.3 billion US$.
Position Summary:
This role is responsible for building and expanding the commerci...
Apply for this Job
Submit your application for the Pharmacy Channel position at Joincare Pharma Philippines, Inc..
Apply Now Save for LaterJob Overview
Job Type:
Full-time
Location:
Maynila, Philippines
Posted:
March 04, 2026
Deadline:
April 13, 2026